Page last updated: 2024-10-18

glycerol and Hepatic Encephalopathy

glycerol has been researched along with Hepatic Encephalopathy in 12 studies

Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.

Hepatic Encephalopathy: A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)

Research Excerpts

ExcerptRelevanceReference
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."5.39Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. ( Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013)
" Recent studies provide new evidence for the use of lactulose, probiotics and rifaximin, as well as closure of large portosystemic shunts in the treatment of hepatic encephalopathy."4.90Treatment of hyperammonemia in liver failure. ( Jalan, R; Jover-Cobos, M; Khetan, V, 2014)
"Pharmacologic management of hepatic encephalopathy includes a broad range of therapies."2.66Pharmacologic Management of Hepatic Encephalopathy. ( Mahpour, NY; Pioppo-Phelan, L; Reja, M; Rustgi, VK; Tawadros, A, 2020)
"Hepatic encephalopathy is one of the most debilitating clinical manifestations of cirrhosis and associated with increased morbidity and mortality."2.61Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy. ( Alsahhar, JS; Rahimi, RS, 2019)
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."1.39Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. ( Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's0 (0.00)18.2507
2000's1 (8.33)29.6817
2010's8 (66.67)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Mahpour, NY1
Pioppo-Phelan, L1
Reja, M1
Tawadros, A1
Rustgi, VK1
Alimirah, M1
Sadiq, O1
Gordon, SC1
Alsahhar, JS1
Rahimi, RS2
Rockey, DC3
Vierling, JM2
Mantry, P2
Ghabril, M2
Brown, RS2
Alexeeva, O1
Zupanets, IA1
Grinevich, V1
Baranovsky, A1
Dudar, L1
Fadieienko, G1
Kharchenko, N1
Klaryts'ka, I1
Morozov, V1
Grewal, P1
McCashland, T1
Reddy, KG1
Reddy, KR1
Syplyviy, V1
Bass, NM1
Dickinson, K2
Norris, C2
Coakley, D2
Mokhtarani, M2
Scharschmidt, BF2
Córdoba, J1
Ventura-Cots, M1
Diaz, GA1
Rhead, W1
Berry, SA1
Lichter-Konecki, U1
Feigenbaum, A1
Schulze, A1
Longo, N1
Bartley, J1
Berquist, W1
Gallagher, R1
Smith, W1
McCandless, SE1
Harding, C1
Moors, T1
Milikien, DA1
Nagamani, SC1
Lemons, C1
Lee, B1
Jover-Cobos, M1
Khetan, V1
Jalan, R1
Sussman, NL1
Ellul, MA1
Gholkar, SA1
Cross, TJ1
Tomikashi, K1
Nomura, Y1
Miyawaki, K1
Shimada, A1
Kanemitsu, D1
Takashima, H1
Abe, M1
Hensle, T1
Blackburn, GL1
O'Donnell, T1
McDermott, WV1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy[NCT00999167]Phase 2189 participants (Actual)Interventional2009-12-31Completed
Effect of Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Liver Cirrhosis; a Randomized Clinical Trial (PEGHE Trial)[NCT04436601]Phase 4102 participants (Anticipated)Interventional2020-03-09Recruiting
A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age With Urea Cycle Disorders, With a Long-Term Safety Extension[NCT00947544]Phase 217 participants (Actual)Interventional2010-03-31Completed
A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)[NCT00992459]Phase 346 participants (Actual)Interventional2009-10-31Completed
A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)[NCT00947297]Phase 360 participants (Actual)Interventional2009-11-30Completed
A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment With HPN-100, in Pediatric Subjects Under 6 Years of Age With Urea Cycle Disorders (UCDs)[NCT01347073]Phase 323 participants (Actual)Interventional2011-07-31Completed
A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders[NCT00551200]Phase 214 participants (Actual)Interventional2007-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Part B: Proportion of Subjects Who Exhibit an HE Episode, Defined as Either of the Following During the Treatment Phase: WH ≥2; WH Grade and Asterixis Grade Increase of 1 Each, if Baseline WH = 0

"An HE event was defined as occurrences of either a West Haven (WH) Grade ≥2 or a WH Grade 1 and asterixis grade increase of 1 (if baseline WH = 0).~The WH criteria are widely used for rating the severity of HE and are summarized below:~Grade 1: trivial lack of awareness, euphoria or anxiety, shortened attention span, impaired performance of addition Grade 2: lethargy or apathy, minimal disorientation for time or place, subtle personality change, inappropriate behavior, impaired performance of subtraction Grade 3: somnolence to semi-stupor but responsive to verbal stimuli, confusion, gross disorientation Grade 4: coma (unresponsive to verbal or noxious stimuli)~Asterixis was assessed after arm and forearm extension along with wrist dorsiflexion for 30 seconds and assigned a grade according to the following criteria:~Grade 1: rare flaps Grade 2: occasional irregular flaps Grade 3: frequent flaps Grade 4: continuous flaps" (NCT00999167)
Timeframe: Part B: 112 Days

Interventionparticipants (Number)
HPN-10019
Placebo32

Time to Meeting the Primary Endpoint

Secondary efficacy endpoint. The time to the first HE episode during the treatment period was calculated using the Kaplan-Meier method. Subjects who did not experience an HE episode were censored at the time of their last asterixis assessment. Subjects who had no post-randomization data for the primary endpoint were considered to have an HE episode at Day 1. (NCT00999167)
Timeframe: 112 Days

InterventionDays (Median)
HPN-100NA
PlaceboNA

Total Number of HE Events

Secondary efficacy endpoint. The total number of HE events during the treatment phase for subjects in the placebo and active arms. (NCT00999167)
Timeframe: 112 Days

InterventionHE event (Number)
HPN-10035
Placebo57

Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score

Changes from Baseline to Day 56 and the Final Visit were compared between treatment groups using an ANCOVA model for the total index RBANS score ). The index score is a sum of the scores for each of the 5 individual domains (immediate memory, visuospatial/constructional, language, attention). The minimum and maximum total index scores are 40 and 160, respectively; a higher score is better. (NCT00999167)
Timeframe: Day 56, Final Visit (D112)

,
Interventionunits on a scale (Least Squares Mean)
Change from Baseline to D56 (Total Score)Change from Baseline to Final Visit (Total Score)
HPN-100-0.5-10.7
Placebo3.2-9.7

Part A: The Rate of AEs and Tolerability of HPN-100

Part A: The rate of AEs and tolerability of 6 mL and 9 mL doses of HPN-100 were considered the primary safety endpoints for Part A. Safety assessments included adverse events, laboratory tests (including ammonia, hematology, coagulation, liver function and serum chemistry parameters), vital signs, physical and neurological examinations, and electrocardiograms. (NCT00999167)
Timeframe: Part A: 28 days

InterventionSubjects (Number)
Any AEGastrointestinal disordersMetabolism and nutrition disordersInfection and infestationsNervous system disordersBlood and lymphatic system disordersInjury, poisoning and procedural complicationsMusculoskeletal and connective tissue disordersPsychiatric disordersAny SAEDeath
HPN-100 BID119744222252

Average Ammonia Values on NaPBA vs. HPN-100 on the Last Day of Treatment With Each Drug (Switch Over)

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionµmol/L (Mean)
HPN-10028.68
NaPBA37.75

Blood Ammonia Control

To evaluate control of blood ammonia by HPN-100 compared with NaPBA in pediatric patients with UCDs. (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμmol∙h/L (Mean)
HPN-100603.83
NaPBA814.62

NH3 Cmax on NaPBA vs. HPN-100 on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμmol/L (Mean)
HPN-10047.77
NaPBA55.66

Plasma PAA (Phenylacetate) AUC0-24 Values on NaPBA vs. HPN-100 on on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμg•h/mL AUC 0-24 (Mean)
HPN-100964
NaPBA773

Plasma PAGN AUC0-24 Values on NaPBA vs. HPN-100 on on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμg*h/mL AUC 0-24 (Mean)
HPN-1001378
NaPBA1015

Plasma PBA (Phenylbutyrate) AUC0-24 Values on NaPBA vs. HPN-100 on on the Last Day of Treatment With Each Drug

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionµg*h/ml AUC 0-24 (Mean)
HPN-100631
NaPBA236

Quality of Life Assessed by the SF-15 Questionnaire

"change from baseline to Month 12.~The SF 15 questionnaire consists of 15 questions that assess the following:~Physical functioning (5 questions)~Emotional functioning (4 questions)~Social functioning (3 questions)~School functioning (3 questions) Items were scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or a 3-point scale (0 [not at all], 2 [sometimes], or 4 [a lot] for the young child self-report). Items were reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, and 4=0. Total score was 0-100 scale (averaged from each functional areas). In the 0-100 scale, 0 is the worst score and 100 is best score.~Improved quality of life was shown by increased total score from baseline to Month 12." (NCT00947544)
Timeframe: 1 year

Interventionscore on a scale (Mean)
HPN-1004.0

Rate (Percentage) of Ammonia Values Above Upper Limit of Normal (ULN) on NaPBA vs. HPN-100

blood samples were collected at pre-dose, 4, 8, 12, 16, 20, and 24 hour post dose on both Day 7 (NaPBA) and Day 14 (HPN-100). (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionpercentage of sample (Number)
HPN-10018.4
NaPBA31.6

Rate of Adverse Events During the Switchover Part of the Study Rate of Adverse Events (Number of Participants Showing Adverse Events)

To evaluate the safety and PK characteristics of HPN-100 compared with sodium phenylbutyrate (NaPBA) in pediatric patients with urea cycle disorders (UCDs) (NCT00947544)
Timeframe: 1 week on each treatment for a total of 2 week.

Interventionparticipants (Number)
HPN-1004
NaPBA2

Urinary PAGN 24-hour Excretion Values on NaPBA vs. HPN-100 (Switch Over)

Urinary PAGN (phenylacetylglutamine) 24-hour excretion. Urine was collect during 0-12 hrs and 12-24 hrs. (NCT00947544)
Timeframe: Day 7 (NaPBA) and Day 14 (HPN-100)

Interventionμg (Mean)
HPN-10012501037
NaPBA12512426

Number and Causes of Hyperammonemic Events (Safety Extension)

"Number of Subjects with at Least One Hyperammonemic Crisis.~Hyperammonemic crisis is defined as follows:~• Clinical symptoms associated with ammonia of ≥ 100 µmol/L" (NCT00947544)
Timeframe: 1 year

,
Interventionparticipants (Number)
Number of subjects with at least 1 HACNumber of Crises
Pre-Enrollment (NaPBA)58
Safety Extension (HPN-100)33

Cmax for PAA of NaPBA and HPN-100 in Plasma

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμg/mL (Mean)
NaPBA52.2
HPN-10038.5

Cmax for PBA of NaPBA and HPN-100 in Plasma

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμg/mL (Mean)
NaPBA80.9
HPN-10051.9

Cmax PAGN of NaPBA and HPN-100 in Plasma

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμg/mL (Mean)
NaPBA78.6
HPN-10086.8

Correlation Between Urinary Phenylacetylglutamine (PAGN) Excretion Over 24 Hours (U-PAGN24-hour Excr) and Venous Ammonia - Area Under the Concentration-time Curve From Time 0 (Predose) to 24 Hours (AUC0-24)

The correlation between 24-hour urinary phenylacetylglutamine (PAGN) excretion (U-PAGN24-hour Excr) and venous ammonia AUC0-24 was summarized and the correlation was tested using the Spearman rank-order correlation. (NCT00992459)
Timeframe: 28 Days

Interventioncorrelation coefficient (Number)
NaPBA0.437
HPN-1000.219

Maximum Ammonia Values Observed on NaPBA Versus HPN-100

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionµmol/L (Mean)
NaPBA70.83
HPN-10060.94

Number and Severity of Symptomatic Hyperammonemic Crises

Severity of symptomatic hyperammonemic crises was measured by peak ammonia level (µmol/L) when it is >= 100 µmol/L. (NCT00992459)
Timeframe: 29 Days

Interventionevents (Number)
NaPBA1
HPN-1000

Rate (Percentage) of Ammonia Values Above Upper Limit of Normal (ULN) on NaPBA Versus HPN-100

NaPBA treated arm: total 345 blood samples were collected. HPN-100 treated arm: 343 blood samples were collected. (NCT00992459)
Timeframe: on Day 14 and Day 28

Interventionsamples (Number)
NaPBA125
HPN-100122

Rate of Adverse Events in Each Treatment Group

(NCT00992459)
Timeframe: 29 Days

Interventionparticipants (Number)
NaPBA23
HPN-10027

The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28.

Blood samples were collected at pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28. Arm A day 14 and Arm B day 28 data were combined as a NaPBA treatment Arm. Arm B day 14 and Arm A day 28 data were combined as a HPN-100 treatment Arm. (NCT00992459)
Timeframe: pre-dose, 2, 4, 8, 12, 16, 20 and 24 hours after first dose on days 14 and 28

Interventionμmol∙h/L (Mean)
NaPBA976.6
HPN-100865.35

U-PAGN24-hour Excr of NaPBA and HPN-100

(NCT00992459)
Timeframe: 24 hours on Day 14 of each treatments

Interventionμg (Mean)
NaPBA13627515
HPN-10013502745

Number and Causes of Hyperammonemic Events

Number of hyperammonemic crises per patient (NCT00947297)
Timeframe: 1 year

Interventionhyperammonemic events (Mean)
HPN-1000.20

Patient Satisfaction With HPN-100

Drug preference will be noted at week 3 (NCT00947297)
Timeframe: Month 1 post dose

Intervention% preferred HPN-100 (Number)
HPN-10090

Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug)

(NCT00947297)
Timeframe: 1 year

Interventionparticipants (Number)
HPN-10033

Blood Ammonia Levels

Venous Ammonia levels over time (NCT00947297)
Timeframe: 1 Year

InterventionUmol/L (Mean)
BaselineMonth 12
HPN-10027.62324.202

Adverse Events

Rate of adverse events during the Safety Extension portion of the protocol ( please note: HPN-100 treatment only during Safety Extension ) (NCT01347073)
Timeframe: 12 months

Interventionparticipants (Number)
HPN-10023

Adverse Events

Rate of adverse events during the Switch-Over portion of the Protocol (NCT01347073)
Timeframe: 2 weeks

Interventionparticipants (Number)
NaPBA0
HPN-1006

Blood Ammonia

24-hour ammonia AUC of blood ammonia levels on Days 1 (NaPBA) and 10 (HPN-100) were compared. Ammonia was assessed at Hour 0 (pre-first dose, fasted), Hour 8 (~2-4 hours after lunch or the second main meal and dose of NaPBA), Hour 12 (~4 hours after the last main meal) and 24 hours post-first dose (pre-first dose on following day, fasted). (NCT01347073)
Timeframe: 2 weeks

Interventionumol/L*hours (Mean)
NaPBA914.43
HPN-100647.63

Frequency of Ammonia Levels Greater Than the Upper Limit of Normal (ULN) on HPN-100 Compared With NaPBA

Ammonia values were converted to SI units (umol/L) and normalized to a standard ULN of 35 umol/L prior to analysis (NCT01347073)
Timeframe: 2 weeks

InterventionAmmonia Values > ULN (Number)
NaPBA22
HPN-1008

Hyperammonemic Crisis

Rate of HAC during pre-enrollment on NaPBA compared to HAC during HPN-100 treatment (NCT01347073)
Timeframe: 1 year

Interventionnumber of crises (Number)
Pre-enrollment29
Long-term Phase12

Number of Subjects Experienced Adverse Events

(NCT00551200)
Timeframe: during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)

Interventionparticipants (Number)
Buphenyl7
HPN-1005

Number of Subjects Experienced Serious Adverse Events

(NCT00551200)
Timeframe: during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)

Interventionparticipants (Number)
Buphenyl1
HPN-1000

Drug Preference for HPN-100 or Buphenyl® (as Assessed by Global Preference Question)

(NCT00551200)
Timeframe: End of Study

Interventionparticipants (Number)
prefer Buphenylprefer HPN-100
Buphenyl to HPN-10019

Pharmacokinetics (Plasma and Urine PK Parameters of Study Drugs and Their Metabolites)

measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)

,
Interventionμg*h/mL (Mean)
AUC0-24 PBA (phenylbutyrate) in plasmaAUC0-24 PAA (phenylacetate) in plasmaAUC0-24 PAGN (phenylacetylglutamine) in plasma
HPN-100 Steady State5405751098
NaPBA Steady State7405961133

Venous Ammonia Levels at the Peak and Mean TNUAC Time-normalized Area Under the Curve)

Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation

,
Interventionμmol/L (Mean)
in peakin TNAUC (time-normalized area under the curve)
HPN-100 Steady State56.326.5
NaPBA Steady State79.138.4

Reviews

7 reviews available for glycerol and Hepatic Encephalopathy

ArticleYear
Pharmacologic Management of Hepatic Encephalopathy.
    Clinics in liver disease, 2020, Volume: 24, Issue:2

    Topics: Acarbose; Amino Acids, Branched-Chain; Anti-Bacterial Agents; Dipeptides; Fecal Microbiota Transplan

2020
Novel Therapies in Hepatic Encephalopathy.
    Clinics in liver disease, 2020, Volume: 24, Issue:2

    Topics: Acetylcarnitine; Albumins; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Flumazenil; GABA M

2020
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
    Current opinion in gastroenterology, 2019, Volume: 35, Issue:3

    Topics: Amino Acids, Aromatic; Amino Acids, Branched-Chain; Ammonia; Dipeptides; Fecal Microbiota Transplant

2019
Treatment of hyperammonemia in liver failure.
    Current opinion in clinical nutrition and metabolic care, 2014, Volume: 17, Issue:1

    Topics: Ammonia; Brain; Glycerol; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose; Phenylbutyrates

2014
Novel Ammonia-Lowering Agents for Hepatic Encephalopathy.
    Clinics in liver disease, 2015, Volume: 19, Issue:3

    Topics: Ammonia; Carbon; Gastrointestinal Agents; Glycerol; Hepatic Encephalopathy; Humans; Ornithine; Oxide

2015
Treatment of Overt Hepatic Encephalopathy.
    Clinics in liver disease, 2015, Volume: 19, Issue:3

    Topics: Amino Acids, Branched-Chain; Ammonia; Arteriovenous Fistula; Dipeptides; Gastrointestinal Agents; Gl

2015
Hepatic encephalopathy due to liver cirrhosis.
    BMJ (Clinical research ed.), 2015, Aug-11, Volume: 351

    Topics: Albumins; Amino Acids; Diagnosis, Differential; Diet; Disaccharides; Drug Resistance; Electroencepha

2015

Trials

1 trial available for glycerol and Hepatic Encephalopathy

ArticleYear
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma

2014
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma

2014
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma

2014
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Adult; Aged; Ammonia; Double-Blind Method; Female; Glutamine; Glycerol; Hepatic Encephalopathy; Huma

2014

Other Studies

4 other studies available for glycerol and Hepatic Encephalopathy

ArticleYear
Drug-induced removal of nitrogen derivatives in urine: a new concept whose time has come.
    Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:3

    Topics: Ammonia; Female; Glycerol; Hepatic Encephalopathy; Humans; Hyperammonemia; Male; Phenylbutyrates

2014
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
    Molecular genetics and metabolism, 2013, Volume: 110, Issue:4

    Topics: Biomarkers; Drug-Related Side Effects and Adverse Reactions; Glutamine; Glycerol; Hepatic Encephalop

2013
[A case of hepatic encephalopathy successfully treated by antegrade glycerin enema through percutaneous endoscopic cecostomy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:1

    Topics: Aged; Ammonia; Cecostomy; Constipation; Endoscopy, Gastrointestinal; Enema; Glycerol; Hepatic Enceph

2008
Intravenous feeding in hepatic failure.
    Surgical forum, 1973, Volume: 24

    Topics: Amino Acids; Amino Acids, Essential; Blood Glucose; Fatty Acids, Nonesterified; Glucose; Glycerol; H

1973